ORTEXORTEX News
Tracking RGA? Get live short interest, options flow, and signals on ORTEX.Sign up free →
RG
Trader NoteRGA

RGA Heads Into Earnings With Bulls Running the Street

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 21 Oct 2026, 19:46

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Reinsurance Group of America enters its November 5 earnings print with the stock up 3.5% on the week, trading at $267.39, and the analyst community pointing broadly higher.

The most compelling story right now is on the Street. Analyst direction has been almost uniformly positive in recent weeks. JPMorgan lifted its target to $297 from $293 on October 15, maintaining Overweight. Barclays raised to $292 from $286 on October 8, also keeping Overweight. Wells Fargo nudged its target up to $292. The lone sceptic is TD Cowen, which today raised its target to $250 from $235 while staying at Hold, a reminder that not everyone is convinced the current price fully reflects the risk. The consensus mean target of $278 now sits roughly 4% below the market price, a tighter implied upside than was available a month ago as the stock has run to meet the bulls. Valuation multiples have moved accordingly: the price-to-book ratio is up about 9% over 30 days, and the trailing P/E has expanded by a similar margin, reflecting the re-rating that follows consistent positive earnings surprises. RGA ranks in the 94th percentile on analyst recommendation differential and the 78th percentile on 90-day EPS momentum, factors that tend to attract incremental institutional demand. Morgan Stanley, carrying an Equal-Weight with a $250 target, sits meaningfully below the market price; that target was last updated in late August and may not fully reflect the stock's subsequent move.

Positioning data tells a quiet story. Short interest is minimal at 1.3% of the free float, and the lending market is wide open: borrow availability is effectively unconstrained, with 64.8 million shares available against fewer than 900,000 sold short. Borrowing costs are below 0.5% annually. The ORTEX short score of 30 reflects a stock where shorts have little conviction and no urgency. Options positioning reinforces that picture. The put/call ratio of 0.17 is well below its 20-day average of 0.23, and the z-score is mildly negative, meaning call volume has been running heavier than puts. Options traders are not buying protection into earnings. That is either a sign of comfort with the fundamental outlook, or a market that is simply not worried about tail risk in reinsurance right now.

The ownership base is stable and institutional. BlackRock holds 10.4% of shares, Fidelity 8.9%, and Harris Associates 7.2%. Harris Associates increased its stake from 5.1% to 6.5% as of its February 2026 filing, a meaningful build from a concentrated value manager. WCM Investment Management added 176,000 shares in its most recent reported period. All 13D and 13G filings on the register are passive; there is no activist on the register. Stakes are as-last-disclosed around the 5% threshold, and a holder can fall below 5% without a further filing.

Insider activity is worth noting for context rather than signal. The most recent trades, from August, were options exercises followed by open-market sales by the EVP and Global Chief Risk Officer. The net insider position over 90 days is negative at roughly $3.7 million sold. The transactions appear to be compensation-related exercise-and-sell activity rather than discretionary selling, though the distinction is worth keeping in mind ahead of the print.

Recent earnings history has been benign. The August print produced a one-day gain of around 4.2% and a five-day gain of nearly 6%. The bull case rests on steady book value growth, improving investment yields with new money yield reaching 6.04%, and a target operating ROE of 13% to 15%. The bear case centres on Asia Pacific headwinds, potential deterioration in benefit ratios in weak global economic conditions, and the corporate expense line coming in above expectations. With the stock having re-rated materially over the past month, the November 5 print becomes as much a test of whether elevated multiples can be sustained as whether the underlying numbers beat.

The key question heading into November 5 is whether the Asia Pacific segment shows stabilisation or further pressure, and whether investment income momentum is strong enough to offset any underwriting softness.

Stocks in this article

See the live data behind this article on ORTEX.

Open RGA on ORTEX →

How this article was generated

Generated
21 Oct 2026, 19:46
Data as of
21 Oct 2026, 19:46
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.